Clinical Trial Update: Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reports ongoing Phase 1/Phase 2 testing of eflornithine (DFMO) with AMXT 1501 for neuroblastoma, CNS tumors, and sarcomas, with recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Teratoid Rhabdoid Tumor
• Diffuse Intrinsic Pontine Glioma
• Embryonal Tumor with Multilayered Rosettes
• Ewing Sarcoma
• Neuroblastoma
• Osteosarcoma

Drugs mentioned

• AMXT 1501 (AMXT-1501)
• Eflornithine (eflornithine)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes | Phase 1, Phase 2 | Status: RECRUITING